Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURVIT intratumoral durvalumab in early cervical cancer
NL-OMON50047Phase 1Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab in Cervical Cancer (CC) (4 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and tolerability of locally administered single-dose durvalumab and Maximum tolerated dose. Started Nov 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON50047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50047.